Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S378000, C514S394000, C514S263100, C514S263230, C514S406000, C514S414000, C514S383000, C544S264000, C544S278000, C548S263200, C548S264200, C548S304700, C548S365700
Reexamination Certificate
active
07148226
ABSTRACT:
The invention relates to compounds of the formula 1and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
REFERENCES:
patent: 3786063 (1974-01-01), Arnold
patent: 4326058 (1982-04-01), Okabe et al.
patent: 4489077 (1984-12-01), Sircar et al.
patent: 4591583 (1986-05-01), Helgstrand et al.
patent: 5504104 (1996-04-01), Ellsworth et al.
patent: 5789440 (1998-08-01), Ellsworth et al.
patent: 5808062 (1998-09-01), Domagala et al.
patent: 5834506 (1998-11-01), Boyer, Jr. et al.
patent: 5840751 (1998-11-01), Ellsworth et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5936128 (1999-08-01), Ellsworth et al.
patent: 6046355 (2000-04-01), Boyer, Jr. et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6512006 (2003-01-01), Boyer, Jr. et al.
patent: 6528510 (2003-03-01), Boyer, Jr. et al.
patent: 2003/0171425 (2003-09-01), Boyer, Jr. et al.
patent: 1 256 628 (2002-11-01), None
patent: WO 95 14011 (1995-05-01), None
patent: WO 95 14012 (1995-05-01), None
patent: WO 98 19997 (1998-05-01), None
patent: WO 015634 (2000-03-01), None
patent: WO 03/095441 (2003-11-01), None
Borchardt, AJ et al ‘preparation of tetrahydopyranones as hepatitis C virus RNA-dependent RNA polymerase inhibitors’ CA 141:243338 (2004).
Tan et al Hepatitis C therapeutics: Current Status and Emerging Strategies, Nature Reviews, Drug Discover, vol. 1, Nov. 2002, 867-881.
Crotty, Ribavirin's antiviral mechanism of action: lethal mutagenesis?, J Mol Med (2002) 80:86-95.
Allen, C.F.H., et al. “The Structure of Certain Polyazaindenes. III. 1,2,3a,7- and 1,3,3a,7-Tetrazaindenes,”J. Org. Chem, 1959, pp. 793-796, vol. 24.
Baginski S., et al. “Mechanism of Action Of A Pestivirus Antiviral Compound,”Proc. Natl. Acad. Sci. USA, 2000, pp. 7981-7986, vol. 97.
Bagshawe, K., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug. Development Research, 1995, pp. 220-230, vol. 34.
Bartenschlager, R., et al., “Molecular Targets In Inhibition Of Hepatitis C Virus Replication”Anitviral Chemistry&Chemotherapy, 1997, pp. 281-301, vol. 8, No. 4.
Bartenschlager, R., et al., “Nonstructural Protein 3 Of The Hepatitis C Virus Encodes A Serine-Type Proteinase Required For Cleavage At The NS3/4 And NS4/5 Junctions,”Journal of Virology, Jul. 1993, pp. 3835-3844, vol. 67, No. 7.
Bergman, J., et al, “Synethesis if Chrysogine, a Metabolite of Penicillium chrysogenum and some related 1-substituted 4-(3H)-Quinazolinones,”Tetrahedron, 1990, pp. 1295-1310, vol. 46.
Bertolini, et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug,”J. Med. Chem., 1997, pp. 2011-2016, vol. 40, issue 13.
Bodor, N, “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research, 1984, pp. 255-331, vol. 13.
Boyer, F.E., et al., 5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalities: Potent Nonpeptidic Inhibitors of HIV Protease,J. Med. Chem., 2000, pp. 843-858, vol. 43, no.
Brown, E.A., et al., “Secondary Structure Of The 5′Nontranslated Regions of Hepatitis C Virus And Pestivirus Genomic RNAs,”Nucleic Acids Research1992, pp. 5041-5045, vol. 20, No. 19.
Bukh, J., et. al., “Sequence Analysis of the 5′ Noncoding Region of Hepatitis C Virus,”Proc. National Academy of Science USA, 1992, pp. 4942-4946, vol. 89.
Bundgaard, H., et al.,Design and Application of Prodrugs, Drug Design and Development, 1991, Krogsgaard-Larsen, et al., editors, Harwood Academic Publishers.
Burke, T.R., et al., “Conformationally Constrained Phosphotyrosyl Mimetics Designed As Monomeric Src Homology 2 Domain Inhibitors,”J. Med. Chem. 1995, pp. 1386-1396, vol. 38.
Carvalho, C.F., et al., “Naturally Occurring Dibenzofurans. Part 6. Synthesis Of Didymic Acid,”J. Chem Soc. Perkin Trans 1, 1984, pp. 1621-1626.
Chavignon, O., et al., “Pyrrolozation Processes Of Vinyl Substitued Imidazo[1,2-α]pyridine, Pyrimidine And 1,8-Naphthyridine,”J. Heterocyclic Chem., 1992, pp. 691-697, vol. 29.
Choo, Q.-L., et al., “Isolation of a cDNA Clone Derived From A Blood-Borne Non-A, Non-B Viral Hepatitis Genome,”Science, Apr. 21, 1989, pp. 359-362, vol. 244.
Cuthbert, J., “Hepatitis C: Progress and Problems”Clinical Microbiology Reviews, Oct. 1994, pp. 505-532, vol. 7, No. 4.
Doria, G., et al, “7-Trans-(2-Pyridylethenyl)-5H-Thiazolo[3,2-a] Pyrimidine-5-Ones: Synthesis And Pharmacological Activity,”Farmaco Ed. Sci., 1985, pp. 885-895.
Doyle, M., et al., “Macrocycle Formation By Catalytic Intramolecular Cyclopropanation. A New General Methodology For The Synthesis Of Macrolides”Journal of the American Chemical Society, 1997, pp. 8826-8837.
Earl, R A., et al., The preparation of 2(1H)-pyridinones and 2,3-dihydro-5(1H)-indolizinones via transition metal mediated cocyclization of alkynes and isocyanates. A novel construction of the antitumor agent camptothecin,Journal of Organic Chemistry, 1984, pp. 4786-4800, vol. 149.
Ellsworth, E.L., et al., “4 Hydroxy -5,6-Dihydro-2H-Pyran-2-ones. 3.Bicyclic and Hetero-Aromatic Ring Systems as 3-Position Scaffolds to Bind to S1'nd S2' of the HIV-1 Protease Enzyme,”Bioorg. Med. Chem. Lett., 1999, pp. 2019-2024, vol. 9, issue 14.
Ferrari, E., et al., “Characterization of Soluble Hepatitis C Virus RNA-Dependent RNA Polymerase Expressed inEscherichia Coli,” Journal of Virology, 1999, pp. 1649-1654, vol. 73, No. 2.
Francki, et al., “Some observations on the Binding Properties of Alfalfa Mosaic Virus to Polystyrene and its significance to indirect ELISA,”Arch. Virol., 1991, pp. 219-235, vol. 2.
Gerecke, M., et al, “New Tetracyclic Derivatives of Imidazo-[1,5-a][1,4]Benzodiazepines and of Imidazo [1,5-a]Thieno[3,2-f][1,4]Diazepines,”Heterocycles, 1994, pp. 693-721, vol. 39, No. 2.
Grakoui, A., et al., “Expression And Identification Of Hepatitis C Virus Polyprotein Cleavage Products”Journal Of Virology, Mar. 1993, pp. 1385-1395, vol. 67, No. 3.
Hagen, et al., “4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease: The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters”J Med.
Hagen, S., et al., “Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity,”J. Med Chem., 1997, pp. 3707-3711, vol. 40, issue 23.
Hénichart, J., et al., “A Convenient Method For The Preparation Of ω-Di-Alkylaminoalkyl Isothiocyanates,”Synthesis, 1980, pp. 311-312.
Hijikata, M., et al., “Gene Mapping Of The Putative Structural Region Of The Hepatitis C Virus Genome By In Vitro Processing Analysis”Proc. Natl. Acad. Sci. USA, Jul. 1991, pp. 5547-5551, vol. 88.
Hwang, S.B., et al., “Hepatitis C Virus NS5B Protein Is A Membrane-Associated Phosphoprotein With A Predominantly Perinuclear Localization,”Virology, 1997, pp. 439-446, vol. 227.
Ishii, et al., “Expression of Hepatitis C Virus NS5B Protein: Characterization of Its RNA Polymerase Activity and RNA Bindint”,Hepatology, 1999, pp. 1227-1235, vol. 29.
Ishizumi, K., et al. “Synthesis And Anxiolytic Activity of N-Substituted Cyclic Imides (1R*, 2S*, 3R*, 4S*)-N-[4[4-(2-Pyrimidinyl)-1-Piperazinyl]butyl]-2,3-Bicyclo[2.2.1]Heptanedicarboximide (Tandospirone) And Related Compounds,”Chem. Pharm Bull., 1991, pp. 2288-2300, vol. 39, No. 9.
Kim, et al., “Hepatitis C Virus NS3 RNA Hel
Borchardt Allen
Gonzalez Javier
Li Hui
Linton Maria Angelica
Tatlock John Howard
Agouron Pharmaceuticals , Inc.
Owens Amelia A.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
Inhibitors of hepatitis C virus RNA-dependent RNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of hepatitis C virus RNA-dependent RNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus RNA-dependent RNA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718193